Danaher (DHR)
(Delayed Data from NYSE)
$253.38 USD
+1.95 (0.78%)
Updated May 10, 2024 04:00 PM ET
After-Market: $253.42 +0.04 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DHR 253.38 +1.95(0.78%)
Will DHR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DHR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DHR
Danaher Corporation (DHR) Is a Trending Stock: Facts to Know Before Betting on It
Markel (MKL) Q1 Earnings, Revenues Miss Estimates, Rise Y/Y
DHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Honeywell (HON) Q1 Earnings Beat, Aerospace Sales Rise Y/Y
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
Other News for DHR
Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals
West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals
Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis
Danaher launches collaboration with John Hopkins University